Eisai didn't reveal sales of its new Alzheimer's disease therapy Leqembi in its third-quarter update, but said the launch was running "ahead of expectations" since the dru
Biogen will have to make the case for its amyotrophic lateral sclerosis (ALS) therapy tofersen to an FDA advisory committee in March before it gets a decision on approval.
Eli Lilly has been unable to secure an accelerated FDA approval for its anti-amyloid Alzheimer's disease therapy donanemab based on mid-stage clinical results, but says it remains on track
Eisai and Biogen have moved swiftly ahead with regulatory filings for their new Alzheimer's therapy lecanemab in the EU, after getting a green light for the anti-amyloid beta antibody in th
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
